Epilepsy is defined as a diverse set of neurological disorders characterized by seizures. These seizures occur due to abnormal electrical activity in the brain. Factors that may lead to epilepsy include, but are not limited to, brain trauma, gene mutations, strokes, brain cancer, and extensive drug and alcohol use. Seizures occur due to a large release of glutamate, which causes a spread of excitation throughout the brain, which propagates the electrical signal and can lead to neuronal death. Hemiplegia-hemiconvulsion-epilepsy syndrome typically occurs in young children under four years of age. Frequently, no cause is found for this disease but certain CNS infections, such as herpes encephalitis, can lead to the syndrome. The seizures that result from this disease are sudden, unilateral clonic convulsions, and can last for a very long time (hours or days) if they are not treated. Post-convulsive flaccid hemiplegia results for all occurences, and in 80% of the patients the hemiplegia is permanent. Aphasia is also present if the dominant side is affected. About 50 million people have epilepsy, with 80% of that population located in developing countries. It is possible to control epilepsy with medicine, but many cases may require surgery in order to relieve symptoms.
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Hemiplegia-hemiconvulsion-epilepsy Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 38 products for the study of Hemiplegia-hemiconvulsion-epilepsy Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Hemiplegia-hemiconvulsion-epilepsy Syndrome is also known as H-h-e Syndrome, Hemiconvulsion-hemiplegia-epilepsy Syndrome.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.